{"id":754944,"date":"2023-05-04T09:58:17","date_gmt":"2023-05-04T13:58:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\/"},"modified":"2023-05-04T09:58:17","modified_gmt":"2023-05-04T13:58:17","slug":"maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\/","title":{"rendered":"MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform"},"content":{"rendered":"

\nWalking Fish to use MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform to engineer novel B-cell based medicines for the treatment of serious diseases
\n<\/h2>\n
\n

ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) — MaxCyte, Inc.<\/a>, (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the signing of a strategic platform license (SPL) with Walking Fish Therapeutics<\/a>, Inc. a biotechnology company that is rapidly advancing B cell-based therapeutics.<\/p>\n

Under the terms of the agreement, Walking Fish obtains non-exclusive clinical and commercial rights to use MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform. In return, MaxCyte is entitled to receive platform licensing fees, clinical milestone payments and sales-based payments.<\/p>\n

\u201cWe are delighted to partner with Walking Fish to help advance their B cell platform and support their innovative approach to develop novel therapies for the treatment of serious diseases,\u201d said Doug Doerfler, President and CEO of MaxCyte<\/strong>.<\/p>\n

Walking Fish is a privately held biotechnology company discovering and developing innovative therapeutics that harness the power of B cells as protein factories and immune modulators. Walking Fish has created a broad technology platform addressing enzyme replacement therapies, oncology, autoimmune disease, and recombinant antibody production. Walking Fish\u2019s first program, WFX-001 employs B cells as protein factories to generate a deficient enzyme in Fabry disease.<\/p>\n

MaxCyte\u2019s ExPERT\u2122 instrument portfolio is the next generation of leading, clinically-validated electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT\u2122 platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. Walking Fish is MaxCyte\u2019s 20th strategic partnership overall, each of which generates pre-commercial milestone revenue and the vast majority of which include sales-based payments.<\/p>\n

\n About MaxCyte\u00a0<\/strong>\n <\/p>\n

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients\u2019 lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today\u2019s processes to innovate tomorrow\u2019s solutions. Our ExPERT\u2122 platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx\u2122, STx\u2122, GTx\u2122 and VLx\u2122; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com<\/a> and follow us on Twitter<\/a> and LinkedIn<\/a>.<\/p>\n

\n About Walking Fish Therapeutics <\/strong>\n <\/p>\n

A leader in B cell medicines, Walking Fish Therapeutics discovers and develops innovative therapeutics that harness the power of B cells as protein factories and immune modulators to treat has made critical advances in engineering technologies to rapidly advance cell-based therapeutics to treat serious diseases, concentrating on oncology, rare diseases, oncology, autoimmune disease, and other life-threatening conditions. For more information and important updates, please visit\u00a0walkingfishtx.com<\/a>.<\/p>\n

\n MaxCyte Contacts:\u00a0<\/strong>\n <\/p>\n

\n US IR Adviser<\/em>
\n
\n Gilmartin Group<\/em>
\n
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com<\/a><\/p>\n

\n US Media Relations<\/em>
\n
\n Spectrum Seismic Collaborative<\/em>
\n
Valerie Enes
+1 408-497-8568
valerie@spectrumscience.com<\/a><\/p>\n

\n Nominated Adviser and Joint Corporate Broker<\/em>\n <\/p>\n

Panmure Gordon
Emma Earl \/ Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500<\/p>\n

\n UK IR Adviser<\/em>
\n
\n Consilium Strategic Communications<\/em>
\n
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Walking Fish to use MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform to engineer novel B-cell based medicines for the treatment of serious diseases ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the signing of a strategic platform license (SPL) with Walking Fish Therapeutics, Inc. a biotechnology company that is rapidly advancing B cell-based therapeutics. Under the terms of the agreement, Walking Fish obtains non-exclusive clinical and commercial rights to use MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform. In return, MaxCyte is entitled to receive platform licensing … <\/p>\n

Continue reading “MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-754944","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Walking Fish to use MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform to engineer novel B-cell based medicines for the treatment of serious diseases ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the signing of a strategic platform license (SPL) with Walking Fish Therapeutics, Inc. a biotechnology company that is rapidly advancing B cell-based therapeutics. Under the terms of the agreement, Walking Fish obtains non-exclusive clinical and commercial rights to use MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform. In return, MaxCyte is entitled to receive platform licensing … Continue reading "MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-04T13:58:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTIwNiM1NTcyNzg2IzIyMDUxNzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform\",\"datePublished\":\"2023-05-04T13:58:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\\\/\"},\"wordCount\":615,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTIwNiM1NTcyNzg2IzIyMDUxNzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\\\/\",\"name\":\"MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTIwNiM1NTcyNzg2IzIyMDUxNzg=\",\"datePublished\":\"2023-05-04T13:58:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTIwNiM1NTcyNzg2IzIyMDUxNzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTIwNiM1NTcyNzg2IzIyMDUxNzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\/","og_locale":"en_US","og_type":"article","og_title":"MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform - Market Newsdesk","og_description":"Walking Fish to use MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform to engineer novel B-cell based medicines for the treatment of serious diseases ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the signing of a strategic platform license (SPL) with Walking Fish Therapeutics, Inc. a biotechnology company that is rapidly advancing B cell-based therapeutics. Under the terms of the agreement, Walking Fish obtains non-exclusive clinical and commercial rights to use MaxCyte\u2019s Flow Electroporation\u00ae technology and ExPERT\u2122 platform. In return, MaxCyte is entitled to receive platform licensing … Continue reading \"MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-04T13:58:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTIwNiM1NTcyNzg2IzIyMDUxNzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform","datePublished":"2023-05-04T13:58:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\/"},"wordCount":615,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTIwNiM1NTcyNzg2IzIyMDUxNzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\/","name":"MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTIwNiM1NTcyNzg2IzIyMDUxNzg=","datePublished":"2023-05-04T13:58:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTIwNiM1NTcyNzg2IzIyMDUxNzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTIwNiM1NTcyNzg2IzIyMDUxNzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-signs-strategic-platform-license-with-walking-fish-therapeutics-to-support-the-development-of-its-innovative-b-cell-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754944","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=754944"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754944\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=754944"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=754944"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=754944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}